The potential commercialization of neuronal replacement therapy using smart polymers
Name
63272900-MIT.pdf
Description
Full printable version
Size
6.93 MB
Format
Adobe PDF
Checksum (MD5)
3a660d5cf2cc639f6f2feaa5d424e070
Author(s)
Dutt, Anindita, 1971-
Advisor(s)
Edward B. Roberts, Robert S. Langer and Mriganka Sur.
Date Issued
2005
Publisher
Massachusetts Institute of Technology
Abstract
NeuroBioChip Device is a programmable, biocompatible, biodegradable, polymer matrix which allows the growth and programming of donor neurons. It creates a microenvironment conducive for neuronal outgrowth and promises a novel cure for neurological disorders caused by localized sites of brain damage, such as Parkinson's disease, stroke, and spinal injury. This chip is being researched in the MIT laboratories of Drs. Robert Langer and Mriganka Sur. My thesis addresses the challenges and possible strategies in commercializing this technology. The need for this treatment was evaluated in the context of current therapies available for the treatment of relevant neurological disorders. Extensive field interviews were conducted. Among other factors, the varying clockspeeds between different components of the device, the unsustainable cost structure and the emerging status of complementary technologies suggested that the development of the therapy is best pursued in collaboration with a large biopharmaceutical or medical device firm.
Description
Thesis (S.M.M.O.T.)--Massachusetts Institute of Technology, Sloan School of Management, Management of Technology Program, 2005.
Includes bibliographical references (leaves 108-122).
Subjects
Management of Technology Program.
MIT Department
Management of Technology Program.
Sloan School of Management
Terms of Use
M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
Persistent DSpace Link
